Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Epilepsy Bio
Aurora, Colorado, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Epilepsy Bio is a biotechnology company focused on developing precision medicines for the treatment of rare and severe forms of epilepsy. The company's primary focus is on the development of small molecule activators targeting KCNQ2/3 potassium channels, which play a critical role in regulating neuronal excitability. By restoring the function of these channels, Epilepsy Bio aims to address the underlying genetic causes of developmental and epileptic encephalopathies. The company is currently advancing its lead programs through pre-clinical development to provide transformative therapies for patients with limited treatment options.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Epilepsy Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epilepsy Bio.